IMPACTIntervening with a Manualised Package to AChieve treatment adherence in people with Tuberculosis (Jan2018 - Dec 2021). ; | |
 | PanACEAThe Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA) is a consortium that brings together scientists from 14 countries to shorten and simplify treatment for TB, through clinical trials and capacity development. UCL-TB PanACEA page;听 ; |
| PanACEA DECODE听 |
| PanACEA SUDUCO听 |
 | RID-TBResearch to Improve Detection and Treatment of Latent TB Infection (Oct 2018-Sep 2023) IGH RID-TB page |
SHINEA randomised trial of shortening treatment for minimal (non-severe) tuberculosis (TB) in African and Indian children (July 2016-Oct 2020).听听听 , , 听 | |
SimpliciTBSimpliciTB is a phase 3 open-label partially randomised clinical trial evaluating the efficacy, safety and tolerability of a novel and potentially shorter drug regimen (BPaMZ) for patients with drug-sensitive (DS) and drug-resistant (MDR-) pulmonary tuberculosis (2018-2022). ; . | |
STREAM Stage 2Evaluation of a Standardised Treatment Regimen of Anti-Tuberculosis Drugs for Patients with MDR-TB (2016-2022). UCL-TB STREAM page; ; | |
| 听 | TB-CHAMPA phase III cluster randomised placebo鈥恈ontrolled trial to assess the efficacy of preventive therapy in child contacts of multidrug鈥恟esistant tuberculosis (2017-2020). ; ; |
 | TB-PRACTECALTB-PRACTECAL is a听phase II/III clinical research project to find short, tolerable and effective treatments for people with drug-resistant tuberculosis (2016-2021).听 UCL page; . |
TRUNCATE-TB听TRUNCATE-TB (Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for drug-sensitive Tuberculosis) is trying to speed up treatment of fully drug-sensitive TB (Duration: Sept 2013-2022) ; ;听 | |
 | UNITE4TB听UNITE4TB 听(Academia and Industry United Innovation and Treatment for Tuberculosis) is a 7-year, 鈧�185 million project that launched in July 2021, and includes 30 partners with representation from academic institutions, public organisations, and pharmaceutical companies听from 13 countries.听听The aim of this programme is to accelerate and improve the clinical evaluation of combinations of existing and novel drugs through Phase 2 trials.听 |
ZeNixZeNix is a phase 3 partially-blinded, randomised trial assessing the safety and efficacy of reducing the amount of Linezolid in the Bedaquiline/Pretomanid/Linezolid (BPaL) regimen for drug-resistant TB (Nov 2017-2022). ; |
Close